Substantial Dose-response Relationship with Clinical Outcome for Lung Stereotactic Body Radiotherapy (SBRT) Delivered via Online Image Guidance

L. Kestin
William Beaumont Hospital

I. Grills
William Beaumont Hospital

M. Guckenberger
University of Wuerzburg

J. Belderbos
Netherlands Cancer Institute

A. J. Hope
Princess Margaret Hospital and University of Toronto

Follow this and additional works at: http://jdc.jefferson.edu/bodinejournal

Part of the Oncology Commons

Let us know how access to this document benefits you

Recommended Citation
Substantial Dose-response Relationship with Clinical Outcome for Lung Stereotactic Body Radiotherapy (SBRT) Delivered via Online Image Guidance

Authors

This accepted abstract is available in Bodine Journal: http://jdc.jefferson.edu/bodinejournal/vol3/iss1/34
Substantial Dose-response Relationship with Clinical Outcome for Lung Stereotactic Body Radiotherapy (SBRT) Delivered via Online Image Guidance

Kestin, L.,1 Grills, I.,1 Guckenberger, M.,2 Belderbos, J.,3 Hope, A.J.,4 Werner-Wasik, M.,5 Sonke, J-J.,3 Bissonnette, J-P.,3 Xiao, Y.,5 Yan, D.1
1William Beaumont Hospital, Royal Oak, MI
2University of Wuerzburg, Wuerzburg, Germany
3Netherlands Cancer Institute, Amsterdam, Netherlands
4Princess Margaret Hospital and University of Toronto, Toronto, ON
5Department of Radiation Oncology, Thomas Jefferson University and Hospitals, Philadelphia, PA

Purpose
To examine potential tumor dose-response relationships with various non-small cell lung cancer (NSCLC) SBRT fractionation regimens delivered with online CT-based image guidance.

Materials/Methods
Four-hundred-four (404) tumors in 382 patients with clinical stage T1-T2 N0 NSCLC were treated with CT-based (Elekta cone-beam CT) online image-guided SBRT at 5 institutions (1998-2009) and had available 3D dose-volume data for the gross tumor volume (GTV) and planning target volume (PTV). All cases were planned with heterogeneity correction. Median maximum tumor dimension was 2.4 cm (range 0.9-7.3 cm). Dose fractionation prescription was according to each institution’s protocol with the most common schedules of 18-20 Gy x 3, 12 Gy x 4, 12 Gy x 5, 12.5 Gy x 3, 7.5 Gy x 8 (median=54 Gy, 3 fractions). Median prescription (Rx) BED10=132 Gy (60-180). Median values (Gy) of 3D planned doses for BED 10 were GTVmin=165, GTVmean=190, GTVmax=207, PTVmin=115, PTV D99=116, PTVmean=166, PTV D1=199, PTVmax=207. Mean follow-up=1.3 years.

Results
Twenty-two (22) cases (5%) had local recurrence (LR) for a 2-year rate of 9%. All BED10 GTV & PTV endpoints were significantly associated with LR (p<0.01) as continuous variables on univariate analysis. PTV mean dose appeared to have the highest correlation with LR with area under ROC curve of 0.74 (p<0.01) and an optimal cut point of 125 Gy BED10. Two-year LR was 4% for PTVmean >125 vs 30% for <125 Gy (p<0.01) with sensitivity=87% and specificity=59% for predicting LR. Two-year LR for Rx BED10 > 105 was 5% vs 19% for < 105 Gy (p<0.01). GTV size was associated with LR on univariate analysis as a continuous variable (p=0.05) with 2-year LR of 5% for < 2.7 cm vs 12% for ≥ 2.7 cm (p=0.01).

Conclusion
There are clear dose-response and tumor volume-response relationships for local control of NSCLC following image-guided SBRT with possible optimal PTVmean BED10 of > 125 Gy in this dataset.